Peptides
Evidence: moderate_human
Mod GRF 1-29 (Modified Growth Hormone Releasing Factor, amino acids 1-29) is a truncated and modified GHRH analog that binds to GHRH receptors on anterior pituitary somatotrophs, activating cAMP via Gs protein/adenylate cyclase and mitogen-activated protein kinase pathways. Without the DAC moiety, it has a short half-life of approximately 30 minutes, producing acute GH pulses that more closely mimic natural pulsatile GH secretion. It also stimulates pituitary gene transcription of GH mRNA, preserving endogenous pituitary reserve.
Standard: Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
Maintenance: Research indicates 100 mcg before bed as a maintenance protocol.
Administration: subcutaneous
Timing: Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.
Duration: 12-24 week cycles with 4-8 week breaks.
The CJC-1295 no-DAC + Ipamorelin stack is the most recommended GH optimization protocol in the peptide community. The short half-life produces GH pulses more closely mimicking natural physiology compared to the DAC version. Saturation dose is approximately 100 mcg (1 mcg/kg) — higher doses show diminishing returns. The interaction with somatostatin means GH release is pulsatile even with exogenous GHRH, preserving the natural feedback loop. Preferred over the DAC version by most optimization practitioners.
Compounding pharmacy (503A/503B). Verify absence of DAC on COA. Often sold simply as 'CJC-1295 no DAC' or 'Mod GRF 1-29'.
Take the free assessment and get personalized recommendations based on your biology and goals.
Get Your Free Protocolor take the assessment →